High Dose Interval Vitamin D Supplementation in Patients With Inflammatory Bowel Disease Receiving Biologic Therapy

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Boston Children's Hospital
Study ID
NCT04331639
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
5 Years - 25 Years
Healthy Volunteers
Not accepted

Interventions

  • vitamin D3 — DIETARY_SUPPLEMENT
    Subjects will receive oral high dose interval vitamin D3, concurrently when they are receiving their biologic treatment for their inflammatory bowel disease every 4-8 weeks.

Study Details

The investigators will be administering oral high dose interval vitamin D, concurrently when participants are receiving biologic therapy for their inflammatory bowel disease. The investigators will be collecting some additional bloodwork and questionnaires at the time of participants infusions.

Key Dates

Start date
Nov 1, 2020
Status verified
Feb 2025
Primary completion
Sep 1, 2024
Completion
Dec 31, 2025

Study Design

Enrollment
50 participants (estimated)

Primary Outcome Measure

vitamin D target [ Time Frame: at study conclusion, up to 64 weeks ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Boston Children's HospitalBostonMassachusetts02115
Rebecca Gordon, MD

Find similar trials in Boston, MA

By condition
Crohn's diseaseUlcerative colitis
By specialty
GastroenterologyInflammatory bowel diseaseAutoimmune disease
By research site
Boston Children's Hospital· Boston, MA

Related Studies